LBRXLB PHARMACEUTICALS INC同业对比
LB PHARMACEUTICALS INC 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LBRX本股 | $1.3B#7 | 1.7x#1 | 3.8x#10 | — | — | 60.1%#3 | — | -7.6%#4 | — | — | 140.1%#3 | — |
| MLYS | $1.4B#1 | — | 2.5x#4 | — | — | 13.0%#4 | — | -28.1%#7 | -41.3%#4 | — | -62.0%#8 | — |
| DMRA | $1.3B#2 | 2.8x#2 | 2.6x#5 | — | — | -878.8%#11 | — | -40.7%#10 | — | — | 189.9%#1 | — |
| KARD | $1.3B#3 | — | 2.2x#3 | — | — | — | — | 0.0%#1 | — | — | — | — |
| OPK | $1.3B#4 | — | 1.1x#1 | 2.1x#1 | -14.9%#5 | -324.0%#10 | -19.3%#3 | -19058.1%#11 | -13.3%#3 | 4#2 | 27.7%#5 | — |
| OMER | $1.3B#5 | 10.3x#3 | — | 17.5x#5 | -34.0%#6 | 97.9%#1 | -166.4%#5 | — | -151.8%#6 | — | 143.4%#2 | — |
| TYRA | $1.3B#6 | — | 3.6x#9 | — | — | -38.7%#6 | — | -33.9%#9 | — | — | 34.9%#4 | — |
| RAPP | $1.2B#8 | — | 2.8x#8 | — | — | -42.4%#7 | — | -26.4%#6 | — | — | -13.1%#7 | — |
| MNKD | $1.2B#9 | — | — | 3.4x#2 | 22.2%#3 | -78.7%#9 | 11.1%#2 | — | 2283.8%#1 | — | — | — |
| SNDX | $1.2B#10 | — | — | 6.8x#4 | 627.8%#1 | 10.5%#5 | -158.4%#4 | — | -143.0%#5 | — | -4.6%#6 | — |
| AVLN | $1.1B#11 | — | 2.8x#7 | — | — | — | — | 0.0%#1 | — | — | — | — |
| SPTX | $1.1B#12 | — | 2.7x#6 | — | — | — | — | 0.0%#1 | — | — | — | — |
| JANX | $1.1B#13 | — | 1.2x#2 | 106.7x#6 | -5.6%#4 | -64.7%#8 | -1576.7%#6 | -12.2%#5 | — | — | — | — |
| HROW | $1.1B#14 | — | 69.5x#11 | 3.9x#3 | 36.4%#2 | 70.6%#2 | 11.2%#1 | -33.8%#8 | 13.2%#2 | 6#1 | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-03。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议